| Ticker |
GOSS
|
| CIK | 0001728117 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121 |
| Website | gossamerbio.com |
| Phone | (858) 922-0718 |
| CEO | Faheem Hasnain |
| Employees | 180 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug SeralutinibGossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study. The study is evaluating seralutinib in patients with Functional Class II and III PAH. Seralutinib is being jointly developed by Gossamer Bio […] Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAHSAN DIEGO, June 16, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and the Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 06, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock optio Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live streamMIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies |
